Literature DB >> 22575202

Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer.

Sumanta K Pal1, Cy A Stein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22575202      PMCID： PMC3845876          DOI： 10.1016/j.clgc.2012.03.007

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  9 in total

1.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Authors:  I F Tannock; D Osoba; M R Stockler; D S Ernst; A J Neville; M J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.

Authors:  Sumanta Kumar Pal; Oliver Sartor
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

Review 6.  Chemotherapy-based treatment for castration-resistant prostate cancer.

Authors:  Bostjan Seruga; Ian F Tannock
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

7.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Authors:  Charles J Ryan; Matthew R Smith; Lawrence Fong; Jonathan E Rosenberg; Philip Kantoff; Florence Raynaud; Vanessa Martins; Gloria Lee; Thian Kheoh; Jennifer Kim; Arturo Molina; Eric J Small
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

8.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
  9 in total
  1 in total

1.  Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report.

Authors:  Shigehisa Kubota; Susumu Kageyama; Masayuki Nagasawa; Akinori Wada; Ryo Ikari; Keiji Tomita; Tetsuya Yoshida; Mitsuhiro Narita; Akihiro Kawauchi
Journal:  Am J Case Rep       Date:  2021-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.